We’ve conducted over 800 projects across Asia Pacific, EMEA, Latin America and North America. The proof of our ability is in our work, so we invite you to browse our case studies. They’re filled with examples of how we enrolled and engaged patients in studies that were just starting, falling behind, and/or in a race to market.
You can filter the case studies by therapeutic area and indication using the drop-downs below.
For the biopharmaceutical company, rapid completion of its study was critical to its commercial success.
Read More »Finding NASH patients for clinical trials can be a major challenge. Acurian has a best-in-class capability to help you find more NASH patients, faster. With a proprietary database of 120 million households, including thousands of confirmed NAFLD patients, plus state-of-the-art, noninvasive screening, we are able to deliver high quality patients who meet your stringent criteria, with fixed budget models.
Read More »A sponsor’s injectable lipid lowering drug was in a first-to-market race against two competitors when it launched an eight-protocol, phase III global program. Six protocols were evaluating the LDL-C lowering efficacy, safety, and tolerability of the drug, and two studies were investigating its ability to reduce major cardiovascular events.
Read More »In order to begin phase III trials, a sponsor needed to complete the phase II study of its intramuscular injection therapy for patients who had diabetic foot ulcers with and without peripheral arterial disease. The plan was to randomize 133 dosed patients over an enrollment period of 26 months.
Read More »A sponsor began a multi-protocol, one-year phase III study to evaluate the safety and tolerability of its drug in subjects with essential hypertension.
Read More »A sponsor was in a tight race to market when it initiated a phase III, two-protocol clinical trial designed to evaluate the efficacy and safety of its inhaler-delivered drug in pediatric patients with persistent asthma.
Read More »Respiratory disease is a core therapeutic area for this sponsor. When it announced the start of its Phase III program for its compound as a potential treatment for severe uncontrolled asthma, the sponsor was facing a crowded field. There were four other products in Phase III and multiple products in Phase II. Because this class of drug was in a race to approval, keeping the program on track and filing a BLA as quickly as possible were paramount.
Read More »A leading company in diabetes began phase III studies with the goal of expanding its portfolio with a next-generation basal insulin analog.
Read More »This seven-year outcomes study is critical to the success of a compound that is expected to build on the sponsor’s
leadership position in diabetes care.
The sponsor needed data from this study as quickly as possible in order to begin its phase III trial in patients with symptomatic GERD not completely responsive to proton pump inhibitors.
Read More »This was an important phase III, two-protocol study for a first-in-class treatment of abdominal uterine bleeding in women with uterine fibroids.
The sponsor was facing significant enrollment challenges. Site start-up was delayed; sites were unable to meet their overly optimistic commitments to deliver enough patients; many patients were unwilling to wash off their current birth control medications to participate...
Read More »This was a critical phase III trial designed to be the most important study in this sponsor’s upcoming FDA submission for an innovative new Type 2 diabetes treatment.
Read More »